Gilead Sciences’ Collaboration Agreement with Goldfinch Bio

Hogan Lovells advised Gilead Sciences on a partnership with Goldfinch Bio, a biotechnology company focused on developing precision therapies for patients with kidney diseases

The strategic collaboration will help to discover, develop and commercialize a pipeline of innovative therapeutics for diabetic kidney disease (DKD) and certain orphan kidney diseases.

The Hogan Lovells team advising Gilead Sciences was led by Adam Golden (Picture) and Anishiya Abrol (counsel), with support from Katherine McGuigan (associate) and Katherine Jeffrey (associate).

Involved fees earner: Anishiya Abrol – Hogan Lovells; Adam Golden – Hogan Lovells; Katherine Jeffery – Hogan Lovells; Katherine McGuigan – Hogan Lovells;

Law Firms: Hogan Lovells;

Clients: Gilead Sciences;